Wells Fargo analyst Stan Berenshteyn initiated coverage of Hinge Health (HNGE) with an Overweight rating and $68 price target The firm views Hinge as the leader in musculoskeletal with 80% win rates, a “widening moat, and software-like margins.” The company has “durable” share gains, expanding adoption, and “untapped growth vectors” supporting long-term growth, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health price target lowered to $70 from $72 at KeyBanc
- Hinge Health: Solidifying MSK Leadership with Undemanding Valuation and Significant Upside into 2026
- Hinge Health price target lowered to $60 from $65 at Barclays
- Hinge Health: Tactical Expense Shift, Intact 2026 Growth and Cash Flow Support Buy Rating
- Hinge Health management to meet virtually with Citizens JMP